Bain utilizza i cookie per migliorare la funzionalità e le prestazioni di questo sito. Ulteriori informazioni in merito si trovano nella nostra Informativa sulla Privacy. Continuando a navigare su questo sito, acconsenti all'uso dei cookie.

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

  • gennaio 04, 2016
  • Tempo di lettura min.

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

BioPharma Dive tapped into the expertise of top thought leaders in the industry to get their takes on what comes next in pricing, M&As, drug development, transparency and much more. "Bain has demonstrated how biopharma leaders have created the most shareholder value by focusing on a few, sustainable leadership positions in Product Categories (distinct from Therapeutic Areas)," said Ashish Singh, the leader of Bain & Company's Global Healthcare practice. "This focused strategy of Category Leadership has been proven to provide superior returns on investment in R&D and commercial."